Abstract
Background/aims
The aim of this study was to evaluate the ability of Model for End-Stage Liver Disease (MELD) in predicting post hepatectomy outcome for hepatocellular carcinoma (HCC).
Methods
Between 2001 and 2005, 94 cirrhotic patients with HCC underwent hepatectomy and were analyzed retrospectively. MELD score associated with postoperative mortality and morbidity, hospital stay, and 3-year survival.
Results
Twenty-eight major and 66 minor resections were performed. Thirty-day mortality rate was 6.4%. MELD ≤ 9 was associated with no perioperative mortality vs 15.3% when MELD > 9 (p = 0.01). Overall morbidity rate was 32%; 21% when MELD ≤ 9 vs 42% when MELD > 9 (p = 0.01). Median hospital stay was 11 days (7 days, when MELD ≤ 9 and 14 days when MELD > 9; p = 0.03). Three-year survival reached 48% (63% when MELD ≤ 9; 30% when MELD > 9; p < 0.01). In multivariate analysis, MELD > 9 (p = 0.01), clinical tumor symptoms (p = 0.04), and American Society of Anesthesiologists score (p = 0.04) were independent predictors of perioperative mortality; MELD > 9 (p = 0.01), tumor size >5 cm (p = 0.01), presence of tumor symptoms (p = 0.02), high tumor grade (p = 0.01), and absence of tumor capsule (p = 0.01) were independent predictors of decreased long-term survival.
Conclusion
MELD score seems to predict outcome of cirrhotic patients with HCC after hepatectomy.
Similar content being viewed by others
References
El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001;5:87–107.
Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70.
Belghiti J, Regimbeau JM, Durand F, Kianmanesh AR, Dondero F, Terris B, Sauvanet A, Farges O, Degos F. Resection of hepatocellular carcinoma: a European experience on 328 cases. Hepatogastroenterology 2002;49:41–46.
Bilimoria MM, Lauwers GY, Doherty DA, Nagorney DM, Belghiti J, Do KA, Regimbeau JM, Ellis LM, Curley SA, Ikai I, Yamaoka Y, Vauthey JN. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001;136(5):528–535.
Franco D, Capussotti L, Smadja C, Bouzari H, Meakins J, Kemeny F, Grange D, Dellepiane M. Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis. Gastroenterology 1990;98:733–738.
Paquet KJ, Gad HA, Lazar A, Koussouris P, Mercado MA, Heine WD, Jachman-Jahn V, Ruppert W. Analysis of factors affecting outcome after hepatectomy of patients with liver cirrhosis and small hepatocellular carcinoma. Eur J Surg 1998;164:513–519.
Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, Curley SA, Pollock RE, Vauthey JN. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002;235:722–731.
Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. Am J Surg 1995;169:589–594.
Lau H, Man K, Fan ST, Yu WC, Lo CM, Wong J. Evaluation of preoperative hepatic function in patients with hepatocellular carcinoma undergoing hepatectomy. Br J Surg 1997;84:1255–1259.
Ercolani G, Grazi GL, Callivà R, Pierangeli F, Cescon M, Cavallari A, Mazziotti A. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. Surgery 2000;127:464–471.
Redaelli CA, Dufour JF, Wagner M, Schilling M, Hüsler J, Krähenbühl L, Büchler MW, Reichen J. Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 2002;235:77–85.
Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10(1):1–7.
Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, Malinchoc M, Chapman RW, Kaplan MM et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992;103(6):1893–1901.
Northup PG, Wanamaker RC, Lee VD, Adams RB, Berg CL. Model for end-stage liver disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 2005;242:244–251.
Befeler AS, Palmer DE, Hoffman M, Longo W, Solomon H, Di Bisceglie AM. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease is superior to Child–Turcotte–Pugh classification in predicting outcome. Arch Surg 2005;140:650–654.
Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, Cha S, Kamath P, Kim R, Nagorney DM. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model for end-stage liver disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 2005;9:1207–1215.
Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G, Zanello M, Grazi GL, Pinna AD. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006;12(6):966–971.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864–871.
Freeman RB Jr, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, Merion R, Wolfe R, Turcotte J, Teperman L. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851–858.
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646–649.
Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmann BG, Poulsen H, Scheuer P, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699.
Committee of the International Hepato-Pancreato-Biliary Association. IHPBA Brisbane 2000 Terminology of Liver Anatomy and Resections. Abingdon: Taylor & Francis, 20002:333–339.
Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York: Springer, 2002, pp 145–153.
Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2000;234:71–78.
Poon RT, Fan ST. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transpl 2004;10(suppl):S39–S45.
Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127(suppl):S248–S260.
Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796–802.
Belghiti J, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, Sommacale D, Dondero F, Lesurtel M, Sauvanet A, Farges O, Kianmanesh R. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003;238:925–928.
Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005;5:307–312.
Imai H, Nakano Y, Kiyosawa K, Tan EM. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993 1;71(1):26–35.
Ledesma F, Echevarria S, Casafont F, Lozano JL, Pons-Romero F. Natural killer cell activity in alcoholic cirrhosis: influence of nutrition. Eur J Clin Nutr 1990;44(10):733–740.
Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM, Poon RT. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008;15(4):962–971.
Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg 2006;243(3):373–379.
Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41(4):707–716.
Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19(3):329–338.
The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000;31(4):840–845.
Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38(3):207–215.
Henderson J, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford) 2003;5(4):243–250.
Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004;91(4):400–408.
Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatol Res 2007;37(Suppl 2):S210–S215.
Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245(6):909–922.
Cho CS, Gonen M, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D’Angelica MI, Blumgart LH, DeMatteo RP. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg 2008;206(2):281–291.
Conflict of interest statement
All authors declare to have no financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work.
The authors: Spiros G Delis, Andreas Bakoyiannis, Nikos Tassopoulos, Christos Dervenis.
Role of the funding source
All authors declare that no sponsors had any involvement in the study.
The authors: Spiros G Delis, Andreas Bakoyiannis, Nikos Tassopoulos, Christos Dervenis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delis, S.G., Bakoyiannis, A., Dervenis, C. et al. Perioperative Risk Assessment for Hepatocellular Carcinoma by Using the MELD Score. J Gastrointest Surg 13, 2268–2275 (2009). https://doi.org/10.1007/s11605-009-0977-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11605-009-0977-5